Alternative splicing variants of genes associated with prostate cancer risk and survival
Disclosed are novel splicing variants of the genes associated with prostate cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. The disclosure also relates risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this disclosure relates to the detection of certain splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1.
1. An siRNA molecule characterized by a length of 15 to 31nucleotides and that inhibits expression of PIK3CD and/or splicing variants thereof comprising:
a) a duplex region comprising a sense region and an antisense region, wherein the sense and antisense regions of the duplex region each consist of 15-31 nucleotides and wherein the sense region includes a PIK3CD variant splice junction and is homologous with at least 15 nucleotides of SEQ ID No. 12; and
b) an overhang region of 0-6 nucleotides.
2. The siRNA molecule of claim 1 , wherein the antisense region is complementary to SEQ ID No. 12.
3. The siRNA molecule of claim 1 , wherein the overhang region is 2 nucleotides in length.
4. The siRNA molecule of claim 1 , wherein the siRNA molecule has no overhang region.
5. The siRNA molecule of claim 1 , wherein the siRNA molecule is chemically synthesized.
6. An siRNA molecule that inhibits expression of PIK3CD and/or splicing variants of, wherein the siRNA is characterized by a length of 15 to 31 nucleotides, includes a PIK3CD variant splice junction, and is homologous with at least 15 nucleotides of SEQ ID No. 12.
7. The siRNA molecule of claim 6 , comprises an overhang region of 0-6 nucleotides.
8. The siRNA molecule of claim 6 wherein the siRNA molecule is a single stranded molecule that can form hairpin structures comprising a duplex region.